These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25906002)

  • 21. Tolvaptan.
    Dubois EA; Rissmann R; Cohen AF
    Br J Clin Pharmacol; 2012 Jan; 73(1):9-11. PubMed ID: 21623874
    [No Abstract]   [Full Text] [Related]  

  • 22. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study).
    Kinugawa K; Inomata T; Sato N; Yasuda M; Shimakawa T; Bando K; Mizuguchi K
    Int Heart J; 2015; 56(2):137-43. PubMed ID: 25740389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levetiracetam-associated hyponatremia.
    Belcastro V; Costa C; Striano P
    Seizure; 2008 Jun; 17(4):389-90. PubMed ID: 18584781
    [No Abstract]   [Full Text] [Related]  

  • 24. Tolvaptan for the treatment of hyponatremia and congestive heart failure.
    Ferrer E
    Drugs Today (Barc); 2010 Mar; 46(3):163-71. PubMed ID: 20467590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [From hyponatremia to tolvaptan].
    Cernaro V; Santoro D; Lacquaniti A; Montalto G; Buemi M
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
    Rollino C; Balbiano R; Caramello P; Roccatello D
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
    Gargani L; Schmidt PH; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of "Vaptans" in treatment of hyponatremia].
    Tanındı A; Töre HF
    Turk Kardiyol Dern Ars; 2015 Apr; 43(3):292-301. PubMed ID: 25906004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA; Cranston IC
    BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan].
    Meyer I; Frank D; Janssens U
    Dtsch Med Wochenschr; 2012 May; 137(21):1096-9. PubMed ID: 22588654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
    BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic efficacy of vasopressin receptor antagonists.
    Ishikawa S; Saito T
    Intern Med; 1998 Feb; 37(2):217-9. PubMed ID: 9550616
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
    Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
    Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyponatremia in heart failure.
    Farmakis D; Filippatos G; Parissis J; Kremastinos DT; Gheorghiade M
    Heart Fail Rev; 2009 Jun; 14(2):59-63. PubMed ID: 18758941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.
    Lee MY; Kang HJ; Park SY; Kim HL; Han E; Lee EK
    Clin Ther; 2014 Sep; 36(9):1183-94. PubMed ID: 25151571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
    Petereit C; Zaba O; Teber I; Lüders H; Grohé C
    BMC Pulm Med; 2013 Aug; 13():55. PubMed ID: 23987478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of Tolvaptan in the Perioperative Management of Severe Hyponatremia During Liver Transplantation: A Case Report.
    Parekh A; Rajaram P; Patel G; Subramanian RM
    Transplant Proc; 2017 Dec; 49(10):2399-2401. PubMed ID: 29198689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.